Navigation Links
Infectious Disease Research Institute Receives Grant for Acquisition of Core Research Equipment from M.J. Murdock Charitable Trust

SEATTLE, Oct. 19 /PRNewswire/ -- The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit scientific research institute, recently received a $252,000 grant from the M.J. Murdock Charitable Trust for core research equipment.

The Murdock Trust grant will enable IDRI to assemble an equipment core to enhance its basic research on immune responses against infectious diseases. IDRI's mission is to research and develop technologies to be used against diseases that continue to burden individuals and countries in the developing world.

IDRI projects enabled under the Murdock grant are focused on chronic infections resulting in leishmaniasis, tuberculosis, trachoma, Buruli ulcer, leprosy, and Chagas disease. Together, these diseases present major public health burdens and cause premature death or disability.

Targeted Diseases

-- Leishmaniasis, transmitted by the bite of a sandfly and caused by

Leishmania infection, is endemic in 88 countries. Approximately

15 million new cases of leishmaniasis occur each year. Visceral

leishmaniasis, which causes damage to internal organs, is often fatal

if left untreated.

-- Tuberculosis is a worldwide health problem. Caused by Mycobacterium

tuberculosis infection, every fifteen seconds someone in the developing

world dies of tuberculosis.

-- Leprosy is endemic in areas of Indian, Brazil, Philippines, the

Democratic Republic of Congo, Madagascar, Mozambique, Nepal, and

Tanzania. It is caused by Mycobacterium leprae infection.

-- Chagas disease, caused by Typanosoma cruzi infection, is endemic in

21 countries in Latin America. It is estimated that 18 million people

are affected by this chronic inflammatory disease, which affects the

heart and digestive tract and in some cases results in death.

-- Malaria, a major parasitic disease, is particularly devastating to

children in Africa.

New Equipment and Uses

The Murdock Trust core equipment grant will enable IDRI to purchase large equipment that is difficult to obtain with conventional research grant funding. Once implemented, the equipment core will enable IDRI's researchers to engage in high-throughput and state-of-the-art assays. Expanding IDRI's basic research equipment core will facilitate the investigation of pathogen- induced immune responses and will help identify new treatment strategies for target infections.

"We are confident we can effectively use this generous grant from the Murdock Trust to perform much needed research about diseases that plague so many millions of people around the world," says Steve Reed, Founder and Head of Research and Development of IDRI.

About M.J. Murdock Charitable Trust

The M.J. Murdock Charitable trust was established in 1975 by the late Melvin J. (Jack) Murdock, who co-founded Tektronix, Inc. of Beaverton, Oregon, and resided in Vancouver, Washington. The mission of the Murdock Charitable Trust is to enrich the quality of life in the Pacific Northwest by providing grants to organizations that seek to strengthen the region's educational and cultural base in creative and sustainable ways. Although the major funding interests are education and scientific research, grants are also given to a wide variety of organizations, including those that serve the arts, public affairs, health and medicine, human services, and people with disabilities.

The Murdock Charitable Trust has focused its grant-making efforts in the following five states of the Pacific Northwest: Alaska, Idaho, Montana, Oregon, and Washington. Beyond grant-making and investment, the Murdock Charitable Trust functions to convene groups of people to discuss issues of mutual interest. This practice is of great assistance to the Murdock Charitable Trust in exploring ways of responding to new grant-making opportunities consistent with its mission and, in addition, promotes a sharing of ideas and networking among participants.

For more information, see:

About IDRI

IDRI is a non-profit organization committed to developing technologies to treat "neglected" diseases that place a significant burden on those living in the developing world. IDRI achieves its mission by working closely with industry, universities, and hospitals in developed and developing countries, government and private funding agencies, and the World Health Organization. For more information, go to

SOURCE Infectious Disease Research Institute
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. eMetagens infectious disease technology licensed by WARF
2. Entrepreneurial Spirit Infectious in Milwaukee
3. New PCR Primers for Human Diseases
4. Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System
5. Multiplexed Quantitative Peptide Assays for Protein Biomarkers of Cardiovascular Disease in Human Plasma
6. Th1 and Th2 Balance, Regulation, and Involvement in Disease
7. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
8. Medical College receives $377K to study brain disease
9. Thompsons HHS legacy will include efforts to combat disease in Africa
10. Stem cells produce anti-disease protein in brain experiment
11. Neurognostics pushes early prediction of brain disease
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 27th Annual ... . .   Listeners ... prior to the presentation to download or install any ... available on the website approximately one hour after the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or "the ... results for the quarter ended September 30, 2015. ... dollars and presented under International Financial Reporting Standards ... ," said Andrew Rae , President & ... are not only value enriching for this clinical ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... High Tech Association (MHTA) as one of only three ... the "Software – Small and Growing" category. The Tekne Awards ... who have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
Breaking Biology News(10 mins):